The rationality behind using a peptide instead of an ER-α-based small heterocyclic molecule, is small ER-α inhibitor inherited with a weaker to moderate agonistic effect on ER-α in uterine cancer cells, which can precipitate the risk of endometrial cancer [138,139]. The gene discussed is ESR1; the disease is uterine cancer.